



Neuren forms strategic partnership with Cato BioVentures, Appoints US Chief Medical Officer

SYDNEY, Australia, 11 February 2010: Neuren Pharmaceuticals Limited (ASX:NEU) announced today that it has entered into a strategic master services agreement with Cato BioVentures (CBV), the venture capital affiliate of Cato Research Ltd (CRL). CRL is a leading global contract research organization providing regulatory and clinical research services to the pharmaceutical, biotechnology and medical device industries. As part of the strategic agreement, CBV participated in the Company's recently completed fundraising, investing US\$400,000.

Under the five-year agreement, CRL will be Neuren's preferred partner for clinical development. CRL presently is supporting Neuren's Phase II clinical research program with NNZ-2566, providing site monitoring, data management and safety reporting services for the trial. In addition, Dr. Jackson Snyder, a CRL Assistant Managing Director, will take on the role of Chief Medical Officer for the US operation, including medical oversight of the NNZ-2566 trial. Dr. Snyder is a physician scientist with more than 30 years of experience in clinical trials, pharmaceutical product development, academic research, government operations and clinical medicine. Besides the MD, he holds a PhD in pharmacology and toxicology, an MPH in public health, an MS in forensic science and a law degree.

Commenting on the agreement, Allen Cato, MD, PhD, CRL's President and CEO, said: "We are pleased to be entering into a strategic relationship with Neuren. Their innovative science and clinical strategy and dedication to making a real difference offer great promise for addressing major unmet medical needs with significant public health consequences. For more than 20 years, Cato Research has worked with and invested in companies with creative, exciting programs to help bring their products to market where the potential impact of the technologies on both medical care and company value is great. Neuren certainly fits this mould and we are looking forward to a long and productive partnership."

Larry Glass, Neuren's CEO, said: "The expansion of our relationship with Cato represents a major step forward in the Company's commitment to best-in-class management of drug development. Strategic outsourcing is a cornerstone of our approach to meeting that commitment and Cato will help us to ensure that our clinical development and regulatory activities continue to meet the highest standards as well as to maximize the cost-effectiveness of the operations. I've worked with CRL on a number of projects in the past and fully appreciate the benefits of their experience, professionalism and insight."



About Cato Research

Cato Research is a global contract research and development organization with offices in Canada, U.S., Europe, Israel, India, and South Africa, offering a full range of research services for the development of drugs, medical devices and biologics. www.cato.com

About Neuren

Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury, neurological diseases and conditions, and cancer. The Neuren portfolio comprises seven product families targeting markets with large unmet needs and limited competition. Neuren has two clinical-stage molecules — Motiva™ and NNZ-2566 — focused on a range of acute and chronic neurological conditions as well as a number of drug discovery programs focused on important targets in neurology and, through its subsidiary Perseis Therapeutics Limited, oncology. For more information, please visit www.neurenpharma.com

For more information, contact:

Larry Glass, CEO Tel : +1 301 758 2987